Literature DB >> 29553509

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species.

Joseph Ochaba1, Eva L Morozko2, Jacqueline G O'Rourke3, Leslie M Thompson4.   

Abstract

The accumulation of misfolded proteins is central to pathology in Huntington's disease (HD) and many other neurodegenerative disorders. Specifically, a key pathological feature of HD is the aberrant accumulation of mutant HTT (mHTT) protein into high molecular weight complexes and intracellular inclusion bodies composed of fragments and other proteins. Conventional methods to measure and understand the contributions of various forms of mHTT-containing aggregates include fluorescence microscopy, western blot analysis, and filter trap assays. However, most of these methods are conformation specific, and therefore may not resolve the full state of mHTT protein flux due to the complex nature of aggregate solubility and resolution. For the identification of aggregated mHTT and various modified forms and complexes, separation and solubilization of the cellular aggregates and fragments is mandatory. Here we describe a method to isolate and visualize soluble mHTT, monomers, oligomers, fragments, and an insoluble high molecular weight (HMW) accumulated mHTT species. HMW mHTT tracks with disease progression, corresponds with mouse behavior readouts, and has been beneficially modulated by certain therapeutic interventions1. This approach can be used with mouse brain, peripheral tissues, and cell culture but may be adapted to other model systems or disease contexts.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29553509      PMCID: PMC5931423          DOI: 10.3791/57082

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

1.  Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates.

Authors:  E E Wanker; E Scherzinger; V Heiser; A Sittler; H Eickhoff; H Lehrach
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

Review 2.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

3.  Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Authors:  Emily Mitchell Sontag; Gregor P Lotz; Namita Agrawal; Andrew Tran; Rebecca Aron; Guocheng Yang; Mihaela Necula; Alice Lau; Steven Finkbeiner; Charles Glabe; J Lawrence Marsh; Paul J Muchowski; Leslie M Thompson
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

Review 4.  The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.

Authors:  James R Arndt; Maxmore Chaibva; Justin Legleiter
Journal:  Biomol Concepts       Date:  2015-03

5.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

6.  Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.

Authors:  Yong Man Kim; Won Hee Jang; Martha M Quezado; Yohan Oh; Kwang Chul Chung; Eunsung Junn; M Maral Mouradian
Journal:  J Neurol Sci       Date:  2011-06-08       Impact factor: 3.181

7.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules.

Authors:  Emily Mitchell Sontag; Gregor P Lotz; Guocheng Yang; Christopher J Sontag; Brian J Cummings; Charles G Glabe; Paul J Muchowski; Leslie Michels Thompson
Journal:  J Huntingtons Dis       Date:  2012

Review 9.  Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease.

Authors:  Sangjune Kim; Kyong-Tai Kim
Journal:  Exp Neurobiol       Date:  2014-03-27       Impact factor: 3.261

10.  SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.

Authors:  Jacqueline Gire O'Rourke; Jaclyn R Gareau; Joseph Ochaba; Wan Song; Tamás Raskó; David Reverter; John Lee; Alex Mas Monteys; Judit Pallos; Lisa Mee; Malini Vashishtha; Barbara L Apostol; Thomas Peter Nicholson; Katalin Illes; Ya-Zhen Zhu; Mary Dasso; Gillian P Bates; Marian Difiglia; Beverly Davidson; Erich E Wanker; J Lawrence Marsh; Christopher D Lima; Joan S Steffan; Leslie M Thompson
Journal:  Cell Rep       Date:  2013-07-18       Impact factor: 9.423

View more
  7 in total

1.  Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains.

Authors:  Karen A Sap; Arzu Tugce Guler; Karel Bezstarosti; Aleksandra E Bury; Katrin Juenemann; Jeroen A A Demmers; Eric A Reits
Journal:  Mol Cell Proteomics       Date:  2019-05-28       Impact factor: 5.911

2.  Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Authors:  Joshua D Crapser; Joseph Ochaba; Neelakshi Soni; Jack C Reidling; Leslie M Thompson; Kim N Green
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

3.  Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease.

Authors:  Todd M Greco; Christopher Secker; Eduardo Silva Ramos; Joel D Federspiel; Jeh-Ping Liu; Alma M Perez; Ismael Al-Ramahi; Jeffrey P Cantle; Jeffrey B Carroll; Juan Botas; Scott O Zeitlin; Erich E Wanker; Ileana M Cristea
Journal:  Cell Syst       Date:  2022-02-10       Impact factor: 11.091

4.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018

Review 5.  Strategies to Investigate Ubiquitination in Huntington's Disease.

Authors:  Karen A Sap; Eric A Reits
Journal:  Front Chem       Date:  2020-06-11       Impact factor: 5.221

6.  Discovery of an autophagy inducer J3 to lower mutant huntingtin and alleviate Huntington's disease-related phenotype.

Authors:  Jiahui Long; Xia Luo; Dongmei Fang; Haikun Song; Weibin Fang; Hao Shan; Peiqing Liu; Boxun Lu; Xiao-Ming Yin; Liang Hong; Min Li
Journal:  Cell Biosci       Date:  2022-10-08       Impact factor: 9.584

7.  TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.

Authors:  Ramanath Narayana Hegde; Anass Chiki; Lara Petricca; Paola Martufi; Nicolas Arbez; Laurent Mouchiroud; Johan Auwerx; Christian Landles; Gillian P Bates; Malvindar K Singh-Bains; Mike Dragunow; Maurice A Curtis; Richard Lm Faull; Christopher A Ross; Andrea Caricasole; Hilal A Lashuel
Journal:  EMBO J       Date:  2020-08-05       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.